Axogen Q4 2024 revenue up 15.1% to $49.4M; reports first quarterly net income of $0.4M

Axogen, Inc.

2024-FY EPS reported -$0.23 revenue$187,338,000

Q4 revenue $49.4M (+15.1% YoY); gross margin 76.1% vs 74.6%.
Q4 net income $0.4M ($0.01 EPS) vs net loss $3.9M prior year; adjusted net income $3.5M ($0.07 EPS).
Full-year 2024 revenue $187.3M (+17.8% YoY); adjusted EBITDA $19.8M vs -$1.1M in 2023.
FDA accepted BLA for Avance Nerve Graft; PDUFA goal date Sept 5, 2025; anticipates approval.
2025 guidance: revenue growth 15-17%, gross margin 73-75%, expects positive net cash flow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.